Hormel Foods Corporation — Form 10-Q Summary
Reporting period: Second quarter and six months ended April 28, 2024; comparisons are with the periods ended April 30, 2023. Figures are in U.S. dollars unless noted.
Business context and results
Hormel is a global branded food manufacturer reporting Retail, Foodservice, and International segments. In Q2, growth in Foodservice and International profitability was offset by weaker Retail sales and higher unallocated costs.
| Metric | Q2 2024 | Q2 2023 | Six months 2024 | Six months 2023 |
|---|---|---|---|---|
| Net sales | $2.887B | $2.978B | $5.884B | $5.949B |
| Gross profit / margin | $504M / 17.4% | $491M / 16.5% | $1.013B / 17.2% | $987M / 16.6% |
| Operating income / margin | $252M / 8.7% | $296M / 9.9% | $537M / 9.1% | $585M / 9.8% |
| Net earnings attributable to Hormel | $189M | $217M | $408M | $435M |
| Diluted EPS | $0.34 | $0.40 | $0.74 | $0.79 |
| Adjusted diluted EPS (non-GAAP) | $0.38 | $0.40 | $0.79 | $0.79 |
Financial position, cash flow, and liquidity
- Six-month operating cash flow was $640M, up 55% year over year. Capital expenditures were $107M and dividends paid were $305M.
- Cash and cash equivalents were $1.486B at April 28, up from $737M at fiscal year-end. The increase primarily reflected about $498M of net proceeds from a new debt issue, alongside operating cash generation.
- Total debt was $3.810B, including $957M classified as current, principally the $950M of 0.650% notes due June 2024. The company issued $500M of 4.800% notes due March 2027 and expects to use that funding and cash on hand to repay the maturing notes.
- The $750M revolving credit facility had no outstanding draws; the company reported compliance with debt covenants. Management believes operating cash flow, cash, borrowing capacity, and capital-market access will meet commitments.
- Fiscal 2024 capital expenditures are estimated at $280M. The annual dividend rate increased to $1.13 per share.
Material changes and segment performance
- Q2 sales declined 3.0% and volume fell 3.6%; six-month sales decreased 1.1%, while volume was essentially unchanged.
- Retail: Q2 sales fell 6.7% and segment profit fell 13.6%. Lower whole-bird turkey volume and pricing, other category weakness, and higher SG&A outweighed lower logistics costs. Six-month sales and profit declined 4.5% and 8.4%.
- Foodservice: Q2 sales rose 5.7% and profit 2.7%, supported by volume growth, category strength, and lower logistics costs. Six-month sales and profit increased 7.5% and 6.3%.
- International: Q2 sales declined 7.3%, but profit rose 70.7%, with favorable China costs and growth in several partnerships and Brazil. Six-month sales fell 5.3%, while profit increased 29.1%.
- Q2 SG&A rose 25.5% to $267M, including higher employee and external costs, increased advertising, transform-and-modernize expenses, and pork-antitrust settlements. Advertising was $44M in Q2, up 27%.
Outlook, risks, and unusual items
- For Q3, management expects gross margin roughly comparable with the prior year. Retail segment profit is expected to decline, partly due to lower volume and turkey prices and an unplanned interruption at the Suffolk, Virginia facility. Foodservice profit is expected to be in line with the prior year; International profit is expected to increase significantly.
- Management expects the fiscal 2024 effective tax rate to be 22%–23%, cost savings from its multi-year transform-and-modernize initiative, and full-year advertising expense above the prior year. Raw-material costs, including pork, beef, and feed, are expected to remain volatile and above historical levels.
- Q2 included $23.6M of pretax transform-and-modernize and pork-antitrust settlement expenses. The company agreed to proposed pork-class settlements totaling $11.8M, subject to court approval, and expects to pay approximately $12M in Q3. It continues to defend non-class pork claims; it has not accrued liabilities for the disclosed pork non-class, turkey-antitrust, poultry-wage, or red-meat-wage matters because management does not consider losses probable and cannot reasonably estimate possible losses.
- Highly pathogenic avian influenza was detected in the turkey supply chain in the first half of fiscal 2024 and is expected to reduce turkey production volume during the year. Other stated risks include commodity volatility, labor availability and costs, disease outbreaks, demand softness, operational disruption, litigation, and foreign-exchange exposure.
- The filing reports no material changes to critical accounting estimates and no material changes to previously disclosed risk factors other than the specified labor and livestock/poultry disease updates. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether the June 2024 $950M note maturity is repaid as planned, and the resulting cash and debt levels.
- Whether turkey-supply impacts and the Suffolk facility interruption affect Retail results and production as management anticipates.
- Whether Foodservice demand and International growth meet Q3 expectations, particularly given the cited China and export risks.
- Progress, costs, and realized savings from the transform-and-modernize initiative; assess adjusted results alongside GAAP figures.
- Final court approval and payment of the pork settlements, and developments in remaining antitrust and wage litigation.
- The Garudafood equity-method investment has a reported quoted market value of $275.4M versus a $425.8M original purchase price; confirm subsequent valuation and any impairment disclosures. The filing does not state that an impairment was recognized.